[go: up one dir, main page]

MX2015017865A - Compuestos de pirimidinodiona contra estados cardiacos. - Google Patents

Compuestos de pirimidinodiona contra estados cardiacos.

Info

Publication number
MX2015017865A
MX2015017865A MX2015017865A MX2015017865A MX2015017865A MX 2015017865 A MX2015017865 A MX 2015017865A MX 2015017865 A MX2015017865 A MX 2015017865A MX 2015017865 A MX2015017865 A MX 2015017865A MX 2015017865 A MX2015017865 A MX 2015017865A
Authority
MX
Mexico
Prior art keywords
compounds against
cardiac conditions
against cardiac
pyrimidinedione compounds
pharmaceutically acceptable
Prior art date
Application number
MX2015017865A
Other languages
English (en)
Other versions
MX382520B (es
Inventor
Song Yonghong
Kane Brian
Evanchik Marc
Anderson Robert
Oslob Johan
Aubele Danielle
Charles Fox Jonathan
Lu Puping
Mcdowell Robert
Rodriguez Hector
Sran Arvinder
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51177189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015017865(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of MX2015017865A publication Critical patent/MX2015017865A/es
Publication of MX382520B publication Critical patent/MX382520B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proporcionan compuestos novedosos de pirimidindiona y sus sales farmacéuticamente aceptables, que son útiles para el tratamiento de cardiomiopatía hipertrófica (HCM) y condiciones asociadas con hipertrofia ventricular izquierda o disfunción diastólica. Se describen la síntesis y caracterización de los compuestos y sus sales farmacéuticamente aceptables, así como métodos para tratar HCM y otras formas de enfermedad cardiaca.
MX2015017865A 2013-06-21 2014-06-19 Compuestos de pirimidinodiona contra estados cardiacos. MX382520B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361838088P 2013-06-21 2013-06-21
US201461939655P 2014-02-13 2014-02-13
US201461981366P 2014-04-18 2014-04-18
PCT/US2014/043192 WO2014205223A1 (en) 2013-06-21 2014-06-19 Pyrimidinedione compounds against cardiac conditions

Publications (2)

Publication Number Publication Date
MX2015017865A true MX2015017865A (es) 2016-09-06
MX382520B MX382520B (es) 2025-03-13

Family

ID=51177189

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2021005326A MX2021005326A (es) 2013-06-21 2014-06-19 Compuestos de pirimidinodiona contra estados cardiacos.
MX2015017865A MX382520B (es) 2013-06-21 2014-06-19 Compuestos de pirimidinodiona contra estados cardiacos.
MX2022014414A MX2022014414A (es) 2013-06-21 2015-12-18 Compuestos de pirimidinodiona contra estados cardiacos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021005326A MX2021005326A (es) 2013-06-21 2014-06-19 Compuestos de pirimidinodiona contra estados cardiacos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014414A MX2022014414A (es) 2013-06-21 2015-12-18 Compuestos de pirimidinodiona contra estados cardiacos.

Country Status (38)

Country Link
US (9) US9181200B2 (es)
EP (2) EP3702352A1 (es)
JP (5) JP6603213B2 (es)
KR (4) KR20220020410A (es)
CN (2) CN105473576B (es)
AU (5) AU2014281408B2 (es)
BR (1) BR112015031864B1 (es)
CA (1) CA2915967C (es)
CL (1) CL2015003689A1 (es)
CR (1) CR20160032A (es)
CY (2) CY1122964T1 (es)
DK (1) DK3010910T3 (es)
DO (1) DOP2015000300A (es)
EA (2) EA201891009A1 (es)
ES (1) ES2773250T3 (es)
FI (1) FIC20230036I1 (es)
FR (1) FR23C1047I2 (es)
GT (1) GT201500348A (es)
HR (1) HRP20200379T1 (es)
HU (2) HUE047566T2 (es)
IL (7) IL317628A (es)
LT (2) LT3010910T (es)
MX (3) MX2021005326A (es)
MY (1) MY190860A (es)
NL (1) NL301253I2 (es)
NO (1) NO2023043I1 (es)
PE (1) PE20160208A1 (es)
PH (2) PH12021552715A1 (es)
PL (1) PL3010910T3 (es)
PT (1) PT3010910T (es)
RS (1) RS59906B1 (es)
SG (2) SG11201510163TA (es)
SI (1) SI3010910T1 (es)
SM (1) SMT202000071T1 (es)
TN (1) TN2015000553A1 (es)
UA (1) UA117929C2 (es)
WO (1) WO2014205223A1 (es)
ZA (1) ZA201508959B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421098B2 (en) 2010-12-23 2016-08-23 Twelve, Inc. System for mitral valve repair and replacement
EP3964176B1 (en) 2011-06-21 2025-05-14 Twelve, Inc. Prosthetic heart valve devices
EA201400481A1 (ru) 2011-10-19 2014-10-30 Твелв, Инк. Искусственные сердечно-клапанные устройства, искусственные митральные клапаны и соответствующие системы и способы
US11202704B2 (en) 2011-10-19 2021-12-21 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
CA2848334C (en) 2011-10-19 2020-10-20 Twelve, Inc. Devices, systems and methods for heart valve replacement
US9039757B2 (en) 2011-10-19 2015-05-26 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CR20160395A (es) 2014-02-13 2016-12-20 Incyte Corp Ciclopropilaminas como inhibidores de lsd1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
MY183499A (en) 2014-02-13 2021-02-22 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
MA51438A (fr) 2015-04-03 2021-04-14 Incyte Corp Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
CN106432222A (zh) * 2016-09-19 2017-02-22 丹诺医药(苏州）有限公司 8‑氯‑1‑环丙基‑7‑氟‑9‑甲基‑4‑氧‑4‑氢‑喹嗪‑3‑羧酸酯及其制备方法
CN106946851B (zh) * 2017-03-14 2019-11-12 牡丹江医学院 一种用于预防和治疗肾结石的药物
US10575950B2 (en) 2017-04-18 2020-03-03 Twelve, Inc. Hydraulic systems for delivering prosthetic heart valve devices and associated methods
US10646338B2 (en) 2017-06-02 2020-05-12 Twelve, Inc. Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods
SMT202500413T1 (it) * 2017-08-04 2025-11-10 Myokardia Inc Mavacamten per l’uso nel trattamento di cardiomiopatia ipertrofica
BR112020014428A2 (pt) 2018-01-19 2020-12-01 Cytokinetics, Inc. composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN112867539B (zh) * 2018-08-31 2024-08-06 赛特凯恩蒂克公司 心脏肌小节抑制剂
JP7447110B2 (ja) * 2018-10-29 2024-03-11 マイオカーディア，インク テトラヒドロピラン（ｔｈｐ）－置換二環式－ピリミジンジオン化合物
US11851409B2 (en) * 2019-01-25 2023-12-26 Qingdao Jião Pharmaceutical Technology Co., Ltd Deuterated benzylaminopyrimidinedione derivatives and use thereof
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
CA3157629A1 (en) * 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
SI4097091T1 (sl) * 2020-01-28 2025-05-30 Assia Chemical Industries Ltd. Trdne oblike mavacamtena in postopek za njihovo pripravo
JP2023540485A (ja) * 2020-08-28 2023-09-25 マイオカーディア，インク ミオシンモジュレーターによる治療方法
AU2021381664A1 (en) * 2020-11-20 2023-06-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
CN114539229B (zh) * 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN116507621B (zh) * 2020-11-24 2025-10-17 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
US20240082248A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy's Laboratories Limited Process for preparation of mavacamten and solid state forms thereof
AU2022227712B2 (en) * 2021-02-25 2024-07-04 Cms Research & Development Pte. Ltd. Substituted pyridine-2,4-dione derivatives
AU2022229390A1 (en) 2021-03-04 2023-09-21 Cytokinetics, Inc. Cardiac sarcomere inhibitors
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
CA3211730A1 (en) * 2021-03-17 2022-09-22 Hugh Y. Zhu Nitrogen-containing heterocyclic ketones, preparation methods and medicinal uses thereof
US20240317692A1 (en) * 2021-07-13 2024-09-26 Nippon Soda Co., Ltd. Method for producing uracil compound
JP7315632B2 (ja) * 2021-09-16 2023-07-26 楽天グループ株式会社 特典付与システム、特典付与方法、及びプログラム
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用
EP4461727A4 (en) * 2022-01-27 2025-06-04 Soter Biopharma Pte. Ltd. CRYSTALLINE FORM OF A 7-AZASPIRO[4,5!DECANE-6,10-DIONE COMPOUND AND PROCESS FOR PREPARATION THEREOF
US20250250239A1 (en) 2022-04-13 2025-08-07 Assia Chemical Industries Ltd. Solid state forms of mavacamten and process for preparation thereof
CA3249509A1 (en) 2022-04-26 2023-11-02 MyoKardia, Inc. METHOD OF ADMINISTRATION OF MYOSIN INHIBITORS
CN119053591A (zh) * 2022-05-20 2024-11-29 江苏恒瑞医药股份有限公司 一种三嗪二酮类衍生物的晶型及制备方法
WO2024056096A1 (zh) * 2022-09-16 2024-03-21 江苏豪森药业集团有限公司 一种含氮杂环酮化合物的晶型及其制备方法
IL319671A (en) 2022-09-26 2025-05-01 Edgewise Therapeutics Inc 4,1-Dihydroquinazolinone compounds and their uses
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy
EP4688748A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
WO2024218783A1 (en) * 2023-04-17 2024-10-24 Dasha Pharmaceuticals Private Limited Green chemistry approach for synthesis of mavacamten and its intermediate using novel methodology
IT202300016653A1 (it) 2023-08-03 2025-02-03 Olon Spa Processo per preparare mavacamten e intermedio di processo.
WO2025046606A1 (en) 2023-08-26 2025-03-06 Micro Labs Limited Granules of mavacamten for oral administration
WO2025096779A2 (en) 2023-11-01 2025-05-08 Bristol Myers Squibb Company Methods of treatment with a myosin inhibitor using protein levels
CN120172920A (zh) * 2023-12-20 2025-06-20 福石生物科技(合肥)有限公司 一种肌球蛋白抑制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280877B (de) 1960-11-16 1968-10-24 Robugen Gmbh Verfahren zur Herstellung von in 1-Stellung substituierten 4-Aminouracilen
JPS61205261A (ja) 1985-03-08 1986-09-11 Sagami Chem Res Center ６―置換―５―フルオロウラシル誘導体
JPH0637479B2 (ja) * 1987-12-28 1994-05-18 三井東圧化学株式会社 新規ピリミジン誘導体、その製造法およびそれを含有する抗不整脈剤
US5008267A (en) * 1988-10-29 1991-04-16 Mitsui Toatsu Chemicals, Incorporated Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same
JPH03173885A (ja) 1989-12-01 1991-07-29 Mitsui Toatsu Chem Inc ピリミジンジオン誘導体化合物、該化合物の製造法および該化合物を含む抗不整脈剤
FR2659656B1 (fr) 1990-03-15 1994-09-09 Sanofi Sa Derives de pyrimidinedione-2,4 et medicaments les contenant.
JPH0413669A (ja) * 1990-04-27 1992-01-17 Mitsui Toatsu Chem Inc 新規ピリミジンジオン誘導体及び該化合物を含有する抗不整脈剤
JPH06128238A (ja) 1992-10-20 1994-05-10 Mitsui Toatsu Chem Inc 新規ピリミジンジオン誘導体
DE69500377T2 (de) 1994-08-19 1997-10-09 Mitsui Toatsu Chemicals Pyrimidin-Dion-Derivate und diese enthaltende antiarrhythmische Zusammensetzungen
US5516905A (en) 1994-08-30 1996-05-14 University Of Massachusetts Medical Center Antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections
EP0967209B1 (de) 1998-06-26 2003-01-08 Crompton Vinyl Additives GmbH Neue NH2-modifizierte 6-Aminouracile als Stabilisatoren für halogenhaltige Polymere
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7416856B2 (en) 1999-05-18 2008-08-26 Cytokinetics, Inc. High sensitivity assay for detection of nucleoside diphosphate production
WO2001029010A1 (en) 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
US20030114445A1 (en) 2001-06-15 2003-06-19 Chengxin Zhi N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections
US20030114414A1 (en) 2001-06-15 2003-06-19 Chengxin Zhi Methods for synthesizing substituted pyrimidines
WO2002102769A2 (en) 2001-06-15 2002-12-27 University Of Massachusetts Methods for synthesizing substituted pyrimidines
DE10208460A1 (de) 2002-02-27 2003-09-04 Bayer Ag Uracil-Thioether
EP1553949B1 (en) * 2002-08-13 2007-04-18 Warner-Lambert Company LLC Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
GEP20094679B (en) 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB0908193D0 (en) * 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds

Also Published As

Publication number Publication date
AU2014281408B2 (en) 2018-08-16
PH12015502794B1 (en) 2022-09-02
AU2024202464A1 (en) 2024-05-02
FR23C1047I2 (fr) 2024-11-15
AU2022202298A1 (en) 2022-04-28
MX2021005326A (es) 2022-11-17
EP3010910A1 (en) 2016-04-27
KR20210118470A (ko) 2021-09-30
EP3702352A1 (en) 2020-09-02
KR20220020410A (ko) 2022-02-18
FR23C1047I1 (fr) 2024-01-12
PH12015502794A1 (en) 2016-03-21
MY190860A (en) 2022-05-12
WO2014205223A1 (en) 2014-12-24
IL275837B (en) 2021-09-30
JP2016522263A (ja) 2016-07-28
HK1223930A1 (en) 2017-08-11
IL310829A (en) 2024-04-01
NO2023043I1 (no) 2023-12-01
BR112015031864A2 (pt) 2017-07-25
CY2023027I1 (el) 2024-02-16
US20210346379A1 (en) 2021-11-11
DK3010910T3 (da) 2020-02-17
USRE50050E1 (en) 2024-07-23
DOP2015000300A (es) 2016-03-15
MX2022014414A (es) 2022-12-07
EA030846B1 (ru) 2018-10-31
KR102304121B1 (ko) 2021-09-24
IL317628A (en) 2025-02-01
JP2020019809A (ja) 2020-02-06
KR20160026997A (ko) 2016-03-09
CN105473576A (zh) 2016-04-06
US20240382486A1 (en) 2024-11-21
JP7376556B2 (ja) 2023-11-08
US9181200B2 (en) 2015-11-10
LTPA2023535I1 (es) 2023-12-27
MX382520B (es) 2025-03-13
CA2915967A1 (en) 2014-12-24
JP2025163126A (ja) 2025-10-28
US20200297726A1 (en) 2020-09-24
AU2020204271B2 (en) 2022-01-06
CY2023027I2 (el) 2024-09-20
JP6603213B2 (ja) 2019-11-06
IL243222B (en) 2020-07-30
PL3010910T3 (pl) 2020-07-27
AU2014281408A1 (en) 2016-01-21
ES2773250T3 (es) 2020-07-10
PH12021552715A1 (en) 2022-05-11
CA2915967C (en) 2021-07-20
EA201690066A1 (ru) 2016-05-31
FIC20230036I1 (fi) 2023-12-01
CN105473576B (zh) 2018-10-30
CR20160032A (es) 2016-04-01
SG10201803459TA (en) 2018-05-30
NL301253I1 (es) 2023-12-13
US20230165860A1 (en) 2023-06-01
CN109384729B (zh) 2023-06-30
IL323967A (en) 2025-12-01
JP6980734B2 (ja) 2021-12-15
PE20160208A1 (es) 2016-05-04
IL285971A (en) 2021-10-31
US20180311242A1 (en) 2018-11-01
LTC3010910I2 (es) 2025-08-25
US20170281626A1 (en) 2017-10-05
AU2020204271A1 (en) 2020-07-16
HUS2300042I1 (hu) 2024-01-28
IL302299A (en) 2023-06-01
AU2018264088A1 (en) 2018-12-06
TN2015000553A1 (en) 2017-04-06
ZA201508959B (en) 2022-09-28
CY1122964T1 (el) 2021-10-29
NZ715456A (en) 2021-01-29
JP2022036966A (ja) 2022-03-08
HRP20200379T1 (hr) 2020-06-12
EA201891009A1 (ru) 2018-09-28
LT3010910T (lt) 2020-03-10
JP2024010108A (ja) 2024-01-23
HUE047566T2 (hu) 2020-04-28
IL275837A (en) 2020-08-31
SG11201510163TA (en) 2016-01-28
US20140378464A1 (en) 2014-12-25
UA117929C2 (uk) 2018-10-25
PT3010910T (pt) 2020-02-21
CN109384729A (zh) 2019-02-26
BR112015031864B1 (pt) 2022-02-15
NL301253I2 (nl) 2024-01-10
SMT202000071T1 (it) 2020-03-13
CL2015003689A1 (es) 2016-10-14
SI3010910T1 (sl) 2020-04-30
KR20230144117A (ko) 2023-10-13
KR102359158B1 (ko) 2022-02-08
IL243222A0 (en) 2016-02-29
GT201500348A (es) 2018-12-20
RS59906B1 (sr) 2020-03-31
US20160030428A1 (en) 2016-02-04
US9585883B2 (en) 2017-03-07
EP3010910B1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
MX2015017865A (es) Compuestos de pirimidinodiona contra estados cardiacos.
DOP2022000172A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
UY34305A (es) Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
MX2016008624A (es) Inhibidores de serina/treonina cinasa.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX2024004892A (es) Compuestos de pirimidinodiona biciclica sustituidos con tetrahidropirano (thp).
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
MX2018004664A (es) Antagonistas de ep4.
MX2017014830A (es) Metodo para tratar las enfermedades roya del cafe, mancha negra de los citricos, sarna de los citricos y sigatoka negra de la banana.
RU2014146038A (ru) Способ лечения болезни де кервена
AR103227A1 (es) Anticuerpos anti-csf1r para el tratamiento de svp